|
1
|
Li T, Zhang H, Lian M, He Q, Lv M, Zhai L,
Zhou J, Wu K and Yi M: Global status and attributable risk factors
of breast, cervical, ovarian, and uterine cancers from 1990 to
2021. J Hematol Oncol. 18:52025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bohlin KS, Brännström M and Dahm-Kähler P:
Gynecological cancer during pregnancy-from a gyne-oncological
perspective. Acta Obstet Gynecol Scand. 103:761–766. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SH and Baek KH: Regulation of cancer
metabolism by deubiquitinating enzymes: The warburg effect. Int J
Mol Sci. 22:61732021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clague MJ, Urbe S and Komander D: Breaking
the chains: Deubiquitylating enzyme specificity begets function.
Nat Rev Mol Cell Biol. 20:338–352. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen X, Tian L, Zhang L, Gao W, Yu M, Li Z
and Zhang W: Deubiquitinase USP39 promotes SARS-CoV-2 replication
by deubiquitinating and stabilizing the envelope protein. Antiviral
Res. 221:1057902024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wendrich K, Gallant K, Recknagel S,
Petroulia S, Kazi NH, Hane JA, Fuhrer S, Bezstarosti K, O'Dea R,
Demmers J and Gersch M: Discovery and mechanism of
K63-linkage-directed deubiquitinase activity in USP53. Nat Chem
Biol. 21:746–757. 2025. View Article : Google Scholar :
|
|
7
|
Luo C, Yu Y, Zhu J, Chen L, Li D, Peng X,
Liu Z, Li Q, Cao Q, Huang K and Yuan R: Deubiquitinase PSMD7
facilitates pancreatic cancer progression through activating nocth1
pathway via modifying SOX2 degradation. Cell Biosci. 14:352024.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pan Q, Yu F, Jin H, Zhang P, Huang X, Peng
J, Xie X, Li X, Ma N, Wei Y, et al: eIF3f mediates SGOC pathway
reprogramming by enhancing deubiquitinating activity in colorectal
cancer. Adv Sci (Weinh). 10:e23007592023. View Article : Google Scholar
|
|
9
|
Tang X, Qiu J, Chen C, Zhang J, Tan R, Li
W, Huang J, Chen H and Yang Z: STAMBPL1 promotes the progression of
gastric cancer via deubiquitinating IQGAP1 to activate the
JAK2/STAT3 pathway. J Gastroenterol. 61:250–265. 2026. View Article : Google Scholar
|
|
10
|
Xie X, Wang X, Jiang D, Wang J, Fei R,
Cong X, Wei L, Wang Y and Chen H: PPPDE1 is a novel deubiquitinase
belonging to a cysteine isopeptidase family. Biochem Biophys Res
Commun. 488:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suk FM, Chang CC, Sun PC, Ke WT, Chung CC,
Lee KL, Chan TS and Liang YC: MCPIP1 enhances TNF-α-mediated
apoptosis through downregulation of the NF-κB/cFLIP axis. Biology
(Basel). 10:6552021.
|
|
12
|
Huang S, Qi D, Liang J, Miao R, Minagawa
K, Quinn T, Matsui T, Fan D, Liu J and Fu M: The putative tumor
suppressor Zc3h12d modulates toll-like receptor signaling in
macrophages. Cell Signal. 24:569–576. 2012. View Article : Google Scholar
|
|
13
|
Ren J, Yu P, Liu S, Li R, Niu X, Chen Y,
Zhang Z, Zhou F and Zhang L: Deubiquitylating enzymes in cancer and
immunity. Adv Sci (Weinh). 10:e23038072023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu X, Wu Y, Yao M, Chen Z and Li Q: The
other side of the coin: Protein deubiquitination by
ubiquitin-specific protease 1 in cancer progression and therapy.
Future Med Chem. 17:329–345. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye Y, Li M, Pan Q, Fang X, Yang H, Dong B,
Yang J, Zheng Y, Zhang R and Liao Z: Machine learning-based
classification of deubiquitinase USP26 and its cell proliferation
inhibition through stabilizing KLF6 in cervical cancer. Comput Biol
Med. 168:1077452024. View Article : Google Scholar
|
|
16
|
Zhou T, Li X, Zhao F, Zhou J and Sun B:
Lactamase β reprograms lipid metabolism to inhibit the progression
of endometrial cancer through attenuating MDM2-mediated p53
ubiquitination and degradation. Arch Biochem Biophys.
764:1102872025. View Article : Google Scholar
|
|
17
|
Li M, Tian Y, Si L, Fu H, Lai T and Guo R:
OTUD4-mediated inhibition of YAP1 signaling pathway in ovarian
cancer: Implications for macrophage polarization and recruitment.
Int Immunopharmacol. 147:1140112025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L,
Chen Z and Xing F: Drug resistance mechanisms and treatment
strategies mediated by ubiquitin-specific proteases (USPs) in
cancers: New directions and therapeutic options. Mol Cancer.
23:882024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cockram PE, Kist M, Prakash S, Chen SH,
Wertz IE and Vucic D: Ubiquitination in the regulation of
inflammatory cell death and cancer. Cell Death Differ. 28:591–605.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roberts JZ, Crawford N and Longley DB: The
role of ubiquitination in apoptosis and necroptosis. Cell Death
Differ. 29:272–284. 2022. View Article : Google Scholar :
|
|
21
|
Das S, Chandrasekaran AP, Suresh B, Haq S,
Kang JH, Lee SJ, Kim J, Kim J, Lee S, Kim HH, et al: Genome-scale
screening of deubiquitinase subfamily identifies USP3 as a
stabilizer of Cdc25A regulating cell cycle in cancer. Cell Death
Differ. 27:3004–3020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Liu W, Wu Y and Chen C: USP3: Key
deubiquitylation enzyme in human diseases. Cancer Sci.
115:2094–2106. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Shi Y, Niu K, Yang R, Lv Q, Zhang
W, Feng K and Zhang Y: Ubiquitin specific peptidase 3: An emerging
deubiquitinase that regulates physiology and diseases. Cell Death
Discov. 10:2432024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou JM, Dai WX, Wang RJ, Xu WQ, Xiang Z,
Wang YX, Zhang T, Zhao YM, Wang L and Mao AR: Organoid modeling
identifies USP3-AS1 as a novel promoter in colorectal cancer liver
metastasis through increasing glucose-driven histone lactylation.
Acta Pharmacol Sin. 46:1404–1418. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: Gepia: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He Y, Jiang S, Zhong Y, Wang X, Cui Y,
Liang J, Sun Y, Zhu Z, Huang Z and Mao X: Usp7 promotes
non-small-cell lung cancer cell glycolysis and survival by
stabilizing and activating c-Abl. Clin Transl Med. 13:e15092023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu T, Sun T, Chen X, Wu J, Sun X, Liu X,
Yan H, Fu Q, Fan Z, Wang X, et al: Targeting ARPC1B overcomes
immune checkpoint inhibitor resistance in glioblastoma by reversing
pro-tumorigenic macrophage polarization. Cancer Res. 85:1236–1252.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yi J, Li H, Chu B, Kon N, Hu X, Hu J,
Xiong Y, Kaniskan HU, Jin J and Gu W: Inhibition of USP7 induces
p53-independent tumor growth suppression in triple-negative breast
cancers by destabilizing FOXM1. Cell Death Differ. 30:1799–1810.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Sun X and Huang Z: USP7 facilitates
deubiquitination of LRRC42 in colorectal cancer to accelerate
tumorigenesis and augment wnt/β-catenin signaling. Biochim Biophys
Acta Mol Cell Res. 1872:1198592025. View Article : Google Scholar
|
|
30
|
Yin Y, Li Y, Ma B, Ren C, Zhao S and Li J,
Gong Y, Yang H and Li J: Mitochondrial-derived peptide MOTS-c
suppresses ovarian cancer progression by attenuating USP7-mediated
LARS1 deubiquitination. Adv Sci (Weinh). 11:e24056202024.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su D, Ma S, Shan L, Wang Y, Wang Y, Cao C,
Liu B, Yang C, Wang L, Tian S, et al: Ubiquitin-specific protease 7
sustains DNA damage response and promotes cervical carcinogenesis.
J Clin Invest. 128:4280–4296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang N, Xu J, Wang Y, Zhang X and Zhang H:
USP7 promotes cervical cancer progression by stabilizing mtdh
expression through deubiquitination. J Cancer Res Clin Oncol.
150:1962024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Das S, Chandrasekaran AP, Jo KS, Ko NR, Oh
SJ, Kim KS and Ramakrishna S: HAUSP stabilizes Cdc25A and protects
cervical cancer cells from DNA damage response. Biochim Biophys
Acta Mol Cell Res. 1867:1188352020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li N, Geng F, Liang SM and Qin X: USP7
inhibits TIMP2 by up-regulating the expression of EZH2 to activate
the NF-κB/PD-L1 axis to promote the development of cervical cancer.
Cell Signal. 96:1103512022. View Article : Google Scholar
|
|
35
|
Dufner A and Knobeloch KP:
Ubiquitin-specific protease 8 (USP8/UBPy): A prototypic multidomain
deubiquitinating enzyme with pleiotropic functions. Biochem Soc
Trans. 47:1867–1879. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan M, Zhao C, Wei N, Wu X, Cui J and Xing
Y: High expression of ubiquitin-specific protease 8 (USP8) is
associated with poor prognosis in patients with cervical squamous
cell carcinoma. Med Sci Monit. 24:4934–4943. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jeong M, Lee EW, Seong D, Seo J, Kim JH,
Grootjans S, Kim SY, Vandenabeele P and Song J: USP8 suppresses
death receptor-mediated apoptosis by enhancing FLIPL
stability. Oncogene. 36:458–470. 2017. View Article : Google Scholar
|
|
38
|
Xu Y, Zeng J, Liu K, Li D, Huang S, Fu S,
Ye M, Tao S and Wu J: USP11 promotes lipogenesis and tumorigenesis
by regulating SREBF1 stability in hepatocellular carcinoma. Cell
Commun Signal. 22:5502024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cui L, Yang L, Lai B, Luo L, Deng H, Chen
Z and Wang Z: Integrative and comprehensive pan-cancer analysis of
ubiquitin specific peptidase 11 (USP11) as a prognostic and
immunological biomarker. Heliyon. 10:e345232024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liao Y, Zhou D, Wang P, Yang M and Jiang
N: Ubiquitin specific peptidase 11 as a novel therapeutic target
for cancer management. Cell Death Discov. 8:2922022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin CH, Chang HS and Yu WC: USP11
stabilizes HPV-16E7 and further modulates the E7 biological
activity. J Biol Chem. 283:15681–15688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi S, Huang C, Tang X, Liu H, Feng W and
Chen C: Identification and verification of diagnostic biomarkers
for deep infiltrating endometriosis based on machine learning
algorithms. J Biol Eng. 18:702024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma LZ, Wang A, Lai YH, Zhang J, Zhang XF,
Chen SL and Zhou XY: USP14 inhibition promotes DNA damage repair
and represses ovarian granulosa cell senescence in premature
ovarian insufficiency. J Transl Med. 22:8342024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gong X, Jia L, Zhou L and Hu T: USP14
predicts poorer survival outcomes and promotes tumor progression in
endometrial carcinoma by activating NF-κB signaling. Aging (Albany
NY). 15:12120–12135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu L, Wang J, Yuan X, Yang S, Xu X, Li K,
He Y, Wei L, Zhang J and Tian Y: IU1 suppresses proliferation of
cervical cancer cells through MDM2 degradation. Int J Biol Sci.
16:2951–2963. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu R, Li M, Wang D, Liu C, Xie L, Yang Y,
Gu X, Zhao K, Tian Y and Cai S: USP15 regulates radiation-induced
DNA damage and intestinal injury through K48-linked
deubiquitination and stabilisation of ATM. Mol Med. 30:2052024.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fang R, Jia Z, Xin Y, Zhao K, Qin W, Lu H,
Zhou Y, Yang Y and Fang H: N6-methyladenosine-modification of USP15
regulates chemotherapy resistance by inhibiting LGALS3
ubiquitin-mediated degradation via akt/mtor signaling activation
pathway in hepatocellular carcinoma. Cell Death Discov. 11:32025.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang J, Li C, Hou Y, Liu D, Li Q, Wang Z,
Tang R, Zheng K, Guo H and Wang W: Mir-26a exerts broad-spectrum
antiviral effects via the enhancement of RIG-I-mediated type I
interferon response by targeting USP15. Microbiol Spectr.
12:e03124232024. View Article : Google Scholar :
|
|
49
|
Nishi H, Ono M, Ohno S, Yamanaka Z, Sasaki
T, Ohyashiki K, Ohyashiki JH and Kuroda M: Hypoxia-induced
paclitaxel resistance in cervical cancer modulated by miR-100
targeting of USP15. Gynecol Oncol Rep. 45:1011382023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yaginuma Y, Yoshimoto M and Tokuda A:
USP15 inhibits HPV16 E6 degradation and catalytically inactive
USP15 has reduced inhibitory activity. Acta Virol. 62:147–156.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu L, Chen Z, Wu Y, Xu M, Zhong D, Xu H
and Zhu W: Unraveling role of ubiquitination in drug resistance of
gynecological cancer. Am J Cancer Res. 14:2523–2537. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ducker C and Shaw PE: USP17-mediated
de-ubiquitination and cancer: Clients cluster around the cell
cycle. Int J Biochem Cell Biol. 130:1058862021. View Article : Google Scholar
|
|
53
|
Li A, Wang T, Zhou S, Han J and Wu W:
USP17 regulates preeclampsia by modulating the NF-κB signaling
pathway via deubiquitinating HDAC2. Placenta. 145:9–18. 2024.
View Article : Google Scholar
|
|
54
|
Huang S, Li J, Wu S, Zheng Z, Wang C, Li
H, Zhao L, Zhang X, Huang H, Huang C and Xie Q: C4orf19 inhibits
colorectal cancer cell proliferation by competitively binding to
Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis. Oncogene.
42:1333–1346. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang L, Ma Y, Zhang S, Yang Y and Huang B:
NFATC2 promotes lactate and M2 macrophage polarization through
USP17 in lung adenocarcinoma. Anticancer Drugs. 35:385–396. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ramakrishna S, Suresh B, Lee EJ, Lee HJ,
Ahn WS and Baek KH: Lys-63-specific deubiquitination of SDS3 by
USP17 regulates HDAC activity. J Biol Chem. 286:10505–10514. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
de la Vega M, Burrows JF, McFarlane C,
Govender U, Scott CJ and Johnston JA: The deubiquitinating enzyme
USP17 blocks N-Ras membrane trafficking and activation but leaves
K-Ras unaffected. J Biol Chem. 285:12028–12036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Holicek P, Guilbaud E, Klapp V, Truxova I,
Spisek R, Galluzzi L and Fucikova J: Type I interferon and cancer.
Immunol Rev. 321:115–127. 2024. View Article : Google Scholar
|
|
59
|
Arimoto KI, Miyauchi S, Troutman TD, Zhang
Y, Liu M, Stoner SA, Davis AG, Fan JB, Huang YJ, Yan M, et al:
Expansion of interferon inducible gene pool via USP18 inhibition
promotes cancer cell pyroptosis. Nat Commun. 14:2512023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Diao W, Guo Q, Zhu C, Song Y, Feng H, Cao
Y, Du M and Chen H: USP18 promotes cell proliferation and
suppressed apoptosis in cervical cancer cells via activating AKT
signaling pathway. BMC Cancer. 20:7412020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chandrasekaran AP, Tyagi A, Poondla N,
Sarodaya N, Karapurkar JK, Kaushal K, Park CH, Hong SH, Kim KS and
Ramakrishna S: Dual role of deubiquitinating enzyme USP19 regulates
mitotic progression and tumorigenesis by stabilizing survivin. Mol
Ther. 30:3414–3429. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tyagi A, Karapurkar JK, Colaco JC,
Sarodaya N, Antao AM, Kaushal K, Haq S, Chandrasekaran AP, Das S,
Singh V, et al: USP19 negatively regulates p53 and promotes
cervical cancer progression. Mol Biotechnol. 66:2032–2045. 2024.
View Article : Google Scholar
|
|
63
|
Dyson HJ and Wright PE: How does p53 work?
Regulation by the intrinsically disordered domains. Trends Biochem
Sci. 50:9–17. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yu Z, Dong C, Yang Y, Zheng Z and Ge X:
USP21 stabilizes immune checkpoint of CD276 and serves as an
immunological and tumor prognostic biomarker. Biochem Biophys Res
Commun. 745:1512212025. View Article : Google Scholar
|
|
65
|
Li Z, Liu X, Yu H, Wang S, Zhao S and
Jiang G: USP21 regulates hippo signaling to promote radioresistance
by deubiquitinating FOXM1 in cervical cancer. Hum Cell. 35:333–347.
2022. View Article : Google Scholar
|
|
66
|
Feng T, Ling S, Xu C, Ying L, Su D and Xu
X: Ubiquitin-specific peptidase 22 in cancer. Cancer Lett.
514:30–37. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yang M, Liu YD, Wang YY, Liu TB, Ge TT and
Lou G: Ubiquitin-specific protease 22: A novel molecular biomarker
in cervical cancer prognosis and therapeutics. Tumour Biol.
35:929–934. 2014. View Article : Google Scholar
|
|
68
|
Sheng CL, Jiang BD, Zhang CQ, Huang JH,
Wang Z and Xu C: USP26 suppresses type I interferon signaling by
targeting TRAF3 for deubiquitination. PLoS One. 19:e03077762024.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li L and Zhang X, Li Y, Xiao B, Pei S,
Jiang H and Zhang X: Transcription factor KLF16 activates MAGT1 to
regulate the tumorigenesis and progression of breast cancer. Int J
Mol Med. 50:1152022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lu C, Cai Y, Wu S, Wang Y, Li JB, Xu G and
Ma J: Deubiquitinating enzyme USP39 promotes the growth and
metastasis of gastric cancer cells by modulating the degradation of
rna-binding protein RBM39. J Biol Chem. 300:1077512024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yu J, Yuan S, Song J and Yu S: USP39
interacts with SIRT7 to promote cervical squamous cell carcinoma by
modulating autophagy and oxidative stress via FOXM1. J Transl Med.
21:8072023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li K, Wang Q and Bian H: USP45 acts as an
oncogene to regulate the proliferation of esophageal cancer cells.
Genes Dis. 11:1011352024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tu X, Li C, Sun W, Tian X, Li Q, Wang S,
Ding X and Huang Z: Suppression of cancer cell stemness and drug
resistance via myc destabilization by deubiquitinase USP45
inhibition with a natural small molecule. Cancers (Basel).
15:9302023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Xia G, Guo Y, Zhang J, Han M, Meng X and
Lv J: An overview of the deubiquitinase USP53: A promising
diagnostic marker and therapeutic target. Curr Protein Pept Sci.
25:708–718. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhou Q, Yao X, Wu C, Chen S and Fan D:
Knockdown of ubiquitin-specific protease 53 enhances the
radiosensitivity of human cervical squamous cell carcinoma by
regulating DNA damage-binding protein 2. Technol Cancer Res Treat.
19:15330338209297922020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li Y, Yang C, Xie L, Shi F, Tang M, Luo X,
Liu N, Hu X, Zhu Y, Bode AM, et al: CYLD induces high oxidative
stress and DNA damage through class I HDACS to promote
radiosensitivity in nasopharyngeal carcinoma. Cell Death Dis.
15:952024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sanches JGP, Xu Y, Yabasin IB, Li M, Lu Y,
Xiu X, Wang L, Mao L, Shen J, Wang B, et al: miR-501 is upregulated
in cervical cancer and promotes cell proliferation, migration and
invasion by targeting CYLD. Chem Biol Interact. 285:85–95. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Huang Y, Zhang W, Yu Z, Su H, Zeng B, Piao
J, Wang J and Wu J: A tumor suppressive role of CYLD as a novel
potential DUB of aurora B in cervical cancer. Clin Med Insights
Oncol. 17:117955492311808322023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Xu Z, Zhang N and Shi L: Potential roles
of uch family deubiquitinases in tumorigenesis and chemical
inhibitors developed against them. Am J Cancer Res. 14:2666–2694.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Fang Y and Shen X: Ubiquitin
carboxyl-terminal hydrolases: Involvement in cancer progression and
clinical implications. Cancer Metastasis Rev. 36:669–682. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu S, Garcia-Marques FJ, Shen M, Bermudez
A, Pitteri SJ and Stoyanova T: Ubiquitin C-terminal hydrolase L1 is
a regulator of tumor growth and metastasis in double-negative
prostate cancer. Am J Clin Exp Urol. 12:306–322. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jia Q, Wang H, Xiao X, Sun Y, Tan X, Chai
J, Yang Y, Yin Z, Li M, Wang K and Liu J: UCHL1 acts as a
prognostic factor and promotes cancer stemness in cervical squamous
cell carcinoma. Pathol Res Pract. 247:1545742023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang Y, Ding J, Zhang X and Hua K:
Ubiquitin C-terminal hydrolase l1 promotes lymph node metastasis in
small cell neuroendocrine carcinomas of the cervix. J Int Med Res.
50:30006052210876202022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lei H, Xu H and Wu Y: Role of UCHL3 in
health and disease. Biochem Biophys Res Commun. 734:1506262024.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu T, Fan MQ, Xie XX, Shu QP, Du XH, Qi
LZ, Zhang XD, Zhang MH, Shan G, Du RL and Li SZ: Activation of
CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates
bladder cancer progression. J Transl Med. 21:6562023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wan B, Cheng M, He T and Zhang L: UCHL5
promotes hepatocellular carcinoma progression by promoting
glycolysis through activating wnt/β-catenin pathway. BMC Cancer.
24:6182024. View Article : Google Scholar
|
|
87
|
Song A, Hazlett Z, Abeykoon D, Dortch J,
Dillon A, Curtiss J, Martinez SB, Hill CP, Yu C, Huang L, et al:
Branched ubiquitin chain binding and deubiquitination by UCH37
facilitate proteasome clearance of stress-induced inclusions.
Elife. 10:e727982021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rolen U, Kobzeva V, Gasparjan N, Ovaa H,
Winberg G, Kisseljov F and Masucci MG: Activity profiling of
deubiquitinating enzymes in cervical carcinoma biopsies and cell
lines. Mol Carcinog. 45:260–269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bao L, Wu Y, Ren Z, Huang Y, Jiang Y, Li
K, Xu X, Ye Y and Gui Z: Comprehensive pan-cancer analysis
indicates UCHL5 as a novel cancer biomarker and promotes cervical
cancer progression through the wnt signaling pathway. Biol Direct.
19:1392024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li Z, Zhou L, Jiang T, Fan L, Liu X and
Qiu X: Proteasomal deubiquitinase UCH37 inhibits degradation of
β-catenin and promotes cell proliferation and motility. Acta
Biochim Biophys Sin (Shanghai). 51:277–284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Sturgill IR, Raab JR and Hoadley KA:
Expanded detection and impact of BAP1 alterations in cancer. NAR
Cancer. 6:zcae0452024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Puri S, Chen SN, Chiu YH, Draczkowski P,
Ko KT, Yang TJ, Wang YS, Uchiyama S and Hsu SD: Impacts of
cancer-associated mutations on the structure-activity relationship
of BAP1. J Mol Biol. 434:1675532022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang N, Li Y and Zhou J: miR-31 functions
as an oncomir which promotes epithelial-mesenchymal transition via
regulating BAP1 in cervical cancer. Biomed Res Int.
2017:63614202017.PubMed/NCBI
|
|
94
|
Zou S, Qin B, Yang Z, Wang W, Zhang J,
Zhang Y, Meng M, Feng J, Xie Y, Fang L, et al: CSN6 mediates
nucleotide metabolism to promote tumor development and
chemoresistance in colorectal cancer. Cancer Res. 83:414–427. 2023.
View Article : Google Scholar
|
|
95
|
Du W, Zhang R, Muhammad B and Pei D:
Targeting the COP9 signalosome for cancer therapy. Cancer Biol Med.
19:573–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Gao S, Fang L, Phan LM, Qdaisat A, Yeung
SC and Lee MH: COP9 signalosome subunit 6 (CSN6) regulates
E6AP/UBE3A in cervical cancer. Oncotarget. 6:28026–28041. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang L, Zeng X, Yang G, Liu G and Pan Y:
Pan-cancer analyses of Jab1/COPS5 reveal oncogenic role and
clinical outcome in human cancer. Heliyon. 8:e125532022. View Article : Google Scholar
|
|
98
|
Cao Z, Yang S, Zou J, Jin Y, Zhang Y, Chen
T and Shen Y: CSN5 overexpression promotes the integral progression
of cervical cancer by enhancing ENO3-mediated glycolysis.
Apoptosis. 31:412026. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang F and Zhou Q: Knockdown of BRCC3
exerts an anti-tumor effect on cervical cancer in vitro. Mol Med
Rep. 18:4886–4894. 2018.PubMed/NCBI
|
|
100
|
Hershey JW: Regulation of protein
synthesis and the role of EIF3 in cancer. Braz J Med Biol Res.
43:920–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Shi J, Kahle A, Hershey JW, Honchak BM,
Warneke JA, Leong SP and Nelson MA: Decreased expression of
eukaryotic initiation factor 3f deregulates translation and
apoptosis in tumor cells. Oncogene. 25:4923–4936. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lee JY, Kim HJ, Rho SB and Lee SH: eIF3f
reduces tumor growth by directly interrupting clusterin with
anti-apoptotic property in cancer cells. Oncotarget. 7:18541–18557.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Oikawa D, Shimizu K and Tokunaga F:
Pleiotropic roles of a KEAP1-associated deubiquitinase, OTUD1.
Antioxidants (Basel). 12:3502023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Du J, Fu L, Sui Y and Zhang L: The
function and regulation of otu deubiquitinases. Front Med.
14:542–563. 2020. View Article : Google Scholar
|
|
105
|
Liu Q, Mallette E, Zheng H and Zhang W:
Development of an OTUD1 ubiquitin variant inhibitor. Biochem J.
480:1317–1330. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhou X, Xing Y, Wang Y, Lv M, Zhang P, Zhu
S, Ge J, Liu L, Zhao M, Gong H, et al: OTUD1 regulates cytokine
expression and related pathways in goose fatty liver by promoting
deubiquitination of its target proteins. Poult Sci. 103:1043822024.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zheng S, Li Y, Song X, Wu M, Yu L, Huang
G, Liu T, Zhang L, Shang M, Zhu Q, et al: OTUD1 ameliorates
cerebral ischemic injury through inhibiting inflammation by
disrupting K63-linked deubiquitination of RIP2. J
Neuroinflammation. 20:2812023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wu L, Lin Y, Feng J, Qi Y, Wang X, Lin Q,
Shi W, Zheng E, Wang W, Hou Z, et al: The deubiquitinating enzyme
OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through
regulating the stability of the MCL1 protein. Cancer Cell Int.
19:2222019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Deng H, Han Y, Liu L, Zhang H, Liu D, Wen
J, Huang M and Zhao L: Targeting myeloid leukemia-1 in cancer
therapy: Advances and directions. J Med Chem. 67:5963–5998. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Bossler F, Hoppe-Seyler K and Hoppe-Seyler
F: PI3K/AKT/mTOR signaling regulates the Virus/Host cell crosstalk
in HPV-positive cervical cancer cells. Int J Mol Sci. 20:21882019.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Fan G, Wang F, Chen Y, Zheng Q, Xiong J,
Lv Q, Wu K, Xiong J, Wei L, Li D, et al: The deubiquitinase OTUD1
noncanonically suppresses Akt activation through its N-terminal
intrinsically disordered region. Cell Rep. 42:1119162023.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Li J, Zhang N, Li M, Hong T, Meng W and
Ouyang T: The emerging role of OTUB2 in diseases: From cell
signaling pathway to physiological function. Front Cell Dev Biol.
10:8207812022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Xiao J, Wang L, Zhuang Y, Zhu Q, Li W,
Liao H, Chen X and Liu Z: The deubiquitinase OTUB2 promotes
cervical cancer growth through stabilizing FOXM1. Am J Transl Res.
16:75–84. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Song Y and Wu Q: RBM15 m6 a
modification-mediated OTUB2 upregulation promotes cervical cancer
progression via the AKT/mTOR signaling. Environ Toxicol.
38:2155–2164. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Fu L, Lu K, Jiao Q, Chen X and Jia F: The
regulation and double-edged roles of the deubiquitinase OTUD5.
Cells. 12:11612023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Bai M, Che Y, Lu K and Fu L: Analysis of
deubiquitinase OTUD5 as a biomarker and therapeutic target for
cervical cancer by bioinformatic analysis. PeerJ. 8:e91462020.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Yin F, He H, Zhang B, Zheng J, Wang M,
Zhang M and Cui H: Effect of deubiquitinase ovarian tumor
domain-containing protein 5 (OTUD5) on radiosensitivity of cervical
cancer by regulating the ubiquitination of akt and its mechanism.
Med Sci Monit. 25:3469–3475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Harrigan JA, Jacq X, Martin NM and Jackson
SP: Deubiquitylating enzymes and drug discovery: Emerging
opportunities. Nat Rev Drug Discov. 17:57–78. 2018. View Article : Google Scholar
|
|
119
|
Wang D, Min W, Jiang B, Sun H, Sun C and
Yang P: From concept to application: Exploring the evolution and
potential of DUBTAC technology. Acta Pharm Sin B. 16:770–787. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chen Y, Xue H and Jin J: Applications of
protein ubiquitylation and deubiquitylation in drug discovery. J
Biol Chem. 300:1072642024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Noblejas-Lopez MDM, Tebar-Garcia D,
Lopez-Rosa R, Alcaraz-Sanabria A, Cristobal-Cueto P, Pinedo-Serrano
A, Rivas-Garcia L and Galan-Moya EM: TACkling cancer by targeting
selective protein degradation. Pharmaceutics. 15:24422023.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Henning NJ, Boike L, Spradlin JN, Ward CC,
Liu G, Zhang E, Belcher BP, Brittain SM, Hesse MJ, Dovala D, et al:
Deubiquitinase-targeting chimeras for targeted protein
stabilization. Nat Chem Biol. 18:412–421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Liu J, Yu X, Chen H, Kaniskan HU, Xie L,
Chen X, Jin J and Wei W: TF-DUBTACs stabilize tumor suppressor
transcription factors. J Am Chem Soc. 144:12934–12941. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Liu J, Hu X, Luo K, Xiong Y, Chen L, Wang
Z, Inuzuka H, Qian C, Yu X, Xie L, et al: USP7-based
deubiquitinase-targeting chimeras stabilize AMPK. J Am Chem Soc.
Apr 10–2024. View Article : Google Scholar : Epub ahead of
print.
|
|
125
|
Li S, Hong X, Wei Z, Xie M, Li W, Liu G,
Guo H, Yang J, Wei W and Zhang S: Ubiquitination of the HPV
oncoprotein E6 is critical for E6/E6AP-mediated p53 Degradation.
Front Microbiol. 10:24832019. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gao M, Cui Z, Song H, Li Y, Li A, Zheng J,
Liu L, Lin X, Fu W and Sun Y: IRF4 enhances radiosensitivity of
cervical cancer by inhibiting the PI3K/Akt/mTOR pathway to regulate
autophagy. Cancer Sci. 117:958–971. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Deng S, Yuan P and Sun J: The role of
NF-κB in carcinogenesis of cervical cancer: Opportunities and
challenges. Mol Biol Rep. 51:5382024. View Article : Google Scholar
|
|
128
|
Zhang X, Wang M, Zhang Y, Yang J and Duan
W: Knockdown of CENPU inhibits cervical cancer cell migration and
stemness through the FOXM1/Wnt/β-catenin pathway. Tissue Cell.
81:1020092023. View Article : Google Scholar
|
|
129
|
Li B and Wang B: USP7 enables immune
escape of glioma cells by regulating PD-L1 expression. Immunol
Invest. 51:1921–1937. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Umemura S, Zhu J, Chahine JJ, Kallakury B,
Chen V, Kim IK, Zhang YW, Goto K, He Y and Giaccone G:
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in
thymic epithelial tumors. Lung Cancer. 147:221–228. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ma Z, Zhou M, Chen H, Shen Q and Zhou J:
Deubiquitinase-targeting chimeras (DUBTACs) as a potential
paradigm-shifting drug discovery approach. J Med Chem.
68:6897–6915. 2025. View Article : Google Scholar : PubMed/NCBI
|
